Kalorama Information’s Women’s Health Diagnostic Markets: Global Outlook and Forecast to 2030 offers a comprehensive, data-driven analysis of the global landscape for diagnostic tests that specifically address women’s health across clinical, point-of-care (POC), and over-the-counter (OTC) settings. As global demographics shift—with women living longer than men—healthcare systems are under increasing pressure to recognize and address sex-based differences in disease risk, screening, and treatment. Diagnostics are at the core of this transformation, offering the ability to deliver personalized and timely interventions across a woman’s life span.

This in-depth report forecasts global market revenues for diagnostic tests and systems through 2030, providing regional segmentation and trend analysis across a broad spectrum of diagnostic categories relevant to female health. The study encompasses both established and emerging technologies used in the detection, screening, and monitoring of conditions unique to, or highly prevalent among, women. Market sizing reflects product and system sales, including associated services such as instrument installation and software support.

Key diagnostic sectors covered in the report include:

• Breast and Reproductive Health Imaging: Mammography, CADe/CADx, OB/GYN ultrasound, and breast ultrasound imaging.
• Prenatal and Carrier Screening: Non-invasive prenatal testing (NIPT), carrier screening, and maternal-fetal diagnostics.
• Infectious and Sexually Transmitted Diseases: HPV diagnostics, TORCH immunoassays, and molecular urinary tract infection (UTI) testing.
• Fertility and Pregnancy Testing: Lab-based and POC tests for ovulation, fertility hormones, and pregnancy status.
• Cancer and Chronic Disease Monitoring: Pap tests, ovarian cancer biomarkers, and female-specific autoimmune immunoassays.
• Bone Health and Preventive Diagnostics: Bone densitometry testing and colposcopy systems for early cancer detection.

Each chapter explores the scientific foundations and technological innovations driving growth in its respective category while addressing challenges such as regulatory shifts, reimbursement, market access, and product differentiation. The report draws on interviews with industry experts, input from clinical labs, and extensive primary and secondary research to inform market forecasts and trend assessments.

A diverse group of diagnostic players—ranging from dominant multinationals to nimble niche firms—are profiled in each category. Companies covered include BD, GE Healthcare, Hologic, Roche, Siemens Healthineers, and Thermo Fisher, among others. These firms are actively shaping the future of women's diagnostics through innovation in biomarkers, automation, digital imaging, and home-based testing.

At a time when diagnostic testing influences more than 70% of medical decisions, this report positions women’s health diagnostics not only as a growing market but also as a critical component of precision medicine. The insights contained herein are essential for stakeholders focused on expanding access, improving clinical outcomes, and investing in the next generation of diagnostic solutions tailored to women’s evolving health needs.